Effects of Oral Sildenafil on Mortality in Adults With PAH
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 385 participants.
Also called NCT02060487
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 385 participants
- Registry
-
NCT02060487 -
2013-004362-34
-
- Other papers using this trial's data
- Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Bosnia & Herzegovina, Croatia, Czechia, Germany, Greece, Hong Kong SAR China, Israel, Latvia, Malaysia, Mexico, Poland, Romania, Russia, Serbia, Singapore, South Africa, Spain, Thailand, Türkiye, Ukraine
- Registry status
- Terminated
Technical summary
Registry record NCT02060487. Randomized; quadruple masking; primary purpose treatment. Start 2014-09-22 (actual); primary completion 2021-02-26 (actual). Results posted on 2022-05-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Oral Sildenafil on Mortality in Adults With PAH
- Acronym
- AFFILIATE
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- sildenafil citrate
- Intervention (Drug)
- sildenafil citrate
- Intervention (Drug)
- sildenafil citrate
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Record details
- Record id
cardio:ct-nct02060487- Content hash
d55aeab5d41092732f6035d7ecfb7f591fdb843e38a082f66c73b493406efe52